Dianthus Therapeutics (NASDAQ:DNTH) Trading 8% Higher - Should You Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s stock price was up 8% on Wednesday . The stock traded as high as $24.41 and last traded at $24.08. Approximately 93,002 shares were traded during trading, a decline of 63% from the average daily volume of 251,486 shares. The stock had previously closed at $22.29.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DNTH. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a "buy" rating on the stock. Raymond James raised shares of Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. Oppenheimer lifted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research report on Monday, November 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $46.43.

Dianthus Therapeutics Trading Up 0.4 %

The company has a market cap of $682.28 million, a price-to-earnings ratio of -9.22 and a beta of 1.72. The business's 50 day moving average price is $23.04 and its 200-day moving average price is $25.79.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. AlphaQuest LLC increased its position in Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock worth $91,000 after buying an additional 3,072 shares during the period. Charles Schwab Investment Management Inc. increased its position in Dianthus Therapeutics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock worth $3,641,000 after acquiring an additional 1,092 shares during the period. Rhumbline Advisers raised its stake in Dianthus Therapeutics by 3.8% in the 4th quarter. Rhumbline Advisers now owns 35,933 shares of the company's stock worth $783,000 after purchasing an additional 1,316 shares in the last quarter. R Squared Ltd bought a new stake in Dianthus Therapeutics in the 4th quarter valued at about $26,000. Finally, KBC Group NV acquired a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $35,000. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.